Generalized Arterial Calcification of Infancy Clinical Trial
Official title:
A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency
The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency (including Generalized Arterial Calcification of Infancy Type 1 [GACI] and Autosomal Recessive Hypophosphatemic Rickets Type 2 [ARHR2]) and the early-onset form of ABCC6 Deficiency (Generalized Arterial Calcification of Infancy Type 2 [GACI-2]) longitudinally.
Study INZ701-003 is a multicenter, prospective, longitudinal, observational study to evaluate disease presentation and progression in infant, pediatric, and adult subjects with ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency. The study will gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes [PROs]) of each disease. Subjects will receive the current standard of care available at the clinical site along with additional assessments administered by the study team. Subject participation will consist of a Screening Period and an Observational Period. During the Screening Period, eligibility will be determined. A subject will be enrolled into the study if they meet all eligibility criteria. During the Observational Period, subjects will be assessed for changes in their disease in the following areas: measurements of physiological function (including laboratory testing, anatomical and radiographical assessment of calcification and bone mineralization, performance outcomes, patient, caregiver, and physician reported outcomes) and healthcare utilization. The type and timing of assessments will be based on the age of the subject at the time of testing. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06046820 -
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
|
Phase 3 | |
| Active, not recruiting |
NCT04686175 -
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05734196 -
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
|
Phase 1 | |
| Completed |
NCT03478839 -
Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
|
||
| Active, not recruiting |
NCT05030831 -
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
|
Phase 1/Phase 2 |